Adial Pharmaceuticals, Inc.

NasdaqCM:ADIL Stock Report

Market Cap: US$2.3m

Adial Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ADIL?
Owner TypeNumber of SharesOwnership Percentage
Private Companies2310.0162%
Individual Insiders31,5542.21%
Institutions39,2612.75%
Hedge Funds111,9867.84%
General Public1,244,93887.2%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 443%.

Top Shareholders

Top 25 shareholders own 12.82% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
7.84%
Armistice Capital LLC
111,986US$182.5k732%no data
1.21%
Vinay Shah
17,325US$28.2k0%no data
0.64%
Robertson Gilliland
9,185US$15.0k0%no data
0.62%
Citadel Advisors LLC
8,784US$14.3k52.7%no data
0.44%
The Vanguard Group, Inc.
6,240US$10.2k0%no data
0.44%
Geode Capital Management, LLC
6,229US$10.2k-5.12%no data
0.34%
Jane Street Group, LLC
4,873US$7.9k888%no data
0.28%
Cary Claiborne
4,032US$6.6k65.8%no data
0.18%
Northern Trust Global Investments
2,639US$4.3k0%no data
0.18%
Virtu Financial, Inc.
2,553US$4.2k0%no data
0.15%
XTX Markets Limited
2,083US$3.4k0%no data
0.13%
Manchester Capital Management, LLC
1,923US$3.1k0%no data
0.078%
BlackRock, Inc.
1,110US$1.8k0%no data
0.054%
Sterne Agee Asset Management, Inc.
778US$1.3k0%no data
0.048%
Two Sigma Securities, LLC
682US$1.1k32.9%no data
0.038%
James Newman
541US$881.9-55.2%no data
0.034%
Susquehanna International Group, LLP
483US$787.20%no data
0.03%
Joseph A. Truluck
424US$691.10%no data
0.028%
Private Management Group Inc
400US$652.00%no data
0.026%
UBS Asset Management AG
366US$596.6-51.2%no data
0.016%
MVA 151 Investors LLC
231US$376.60%no data
0.0037%
Tower Research Capital Europe Limited
53US$86.4-1.85%no data
0.0032%
SBI Holdings, Inc.
46US$74.9-16.4%no data
0.0023%
Kevin Schuyler
33US$53.80%no data
0.00098%
Tony Goodman
14US$22.80%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/20 19:23
End of Day Share Price 2026/04/20 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Adial Pharmaceuticals, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian Kemp DolliverBrookline Capital Markets
Theodore O'NeillLitchfield Hills Research, LLC
Jason McCarthyMaxim Group